(Yicai Global) Oct. 10 -- Humanwell Healthcare (Group) Co. [SHA:600079], headquartered in Central China's Hubei province, has gotten the green light to sell a generic drug for type-2 (non-insulin dependent) diabetes mellitus treatment on the US market.

PuraCap Pharmaceutical LLC, in which it owns a 72 percent stake, recently received approval from the US Food and Drug Administration (FDA) for the release of its Pioglitazone Tablet, the company said yesterday.

Pioglitazone Tablet is mainly used to treat type-2 diabetes mellitus. PuraCap submitted the application for the drug's release in November 2014, and invested an aggregate of about USD1 million in its development. Total sales of Pioglitazone Tablets developed by other companies in the American market were USD30 million last year, and approximately USD100 million (CNY660 million) worth of the drugs sold in China, public data shows.

After obtaining FDA approval, Humanwell Healthcare will hasten preparations for product release and generic drug market development in the US, per the statement.

The company founded PuraCap Pharmaceutical LLC jointly with US pharmaceutical firm Enspire Group LLC in 2008. The joint venture specializes in exporting soft capsule medicines and health food products to the European and American markets.